West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript

West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript

Seeking Alpha • 7 hours ago

West Reports Third-Quarter 2026 Results

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2026.

PRNewsWire • 15 hours ago

West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $1.96 per share a year ago.

Zacks Investment Research • 13 hours ago

Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • 10 hours ago

West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised

WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.

Zacks Investment Research • 8 hours ago

Best Dividend Aristocrats For November 2026

Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's 14.15%. Dividend growth among Aristocrats accelerated, with the 2026 average increase now at 4.55%, bolstered by recent double-digit hikes.

Seeking Alpha • 18 hours ago

West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • Oct 28, 2026

WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?

WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.

Zacks Investment Research • Oct 27, 2026

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

Zacks Investment Research • Oct 21, 2026

West Declares Quarterly Dividend

EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend.

PRNewsWire • Oct 19, 2026